Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa

Vaccine

Volumn 29, Issue 11, 2011, Pages 2187-2192

  Mothibeli, Kedibone M ^a   du Plessis, Mignon ^a,b   von Gottberg, Anne ^a,b   Murphy, Ellen ^c   Hoiseth, Susan K ^c   Zlotnick, Gary ^c   Klugman, Keith P ^b,d  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Pfizer Vaccine Research Operations and Strategy   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clonal complex; FHBP; Neisseria meningitidis; Serogroup B; Serosubtype; South Africa

Indexed keywords

BACTERIAL PROTEIN; BINDING PROTEIN; FACTOR H BINDING PROTEIN; FETA PROTEIN; PORIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SOUTH AFRICA;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; DNA, BACTERIAL; GENETIC VARIATION; GENOTYPE; HUMANS; INCIDENCE; MENINGOCOCCAL INFECTIONS; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS, SEROGROUP B; PHENOTYPE; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA;

EID: 79951812892     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.072     Document Type: Article

References (45)

1. Yazdankhah S.P., Kriz P., Tzanakaki G., Kremastinou J., Kalmusova J., Musilek M., et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004, 42(November (11)):5146-5153.
2. Hossain M.A., Ahmed D., Ahmed T., Islam N., Breiman R.F. Increasing isolations of Neisseria meningitidis serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh, 1999-2006. Am J Trop Med Hyg 2009, 80(April (4)):615-618.
3. Pickering L.K., Martone W.J. The meningococcal bacterium. Meningococcal Infections: Recognizing, Treating and Preventing Infections Caused by Neisseria meningitidis 2000, National Foundation for Infectious Diseases, Available at: http://www.nfid.org/_old/library/meningococcal/fs_bacterium.html. Accessed July 2009.
4. Nicolas P., Norheim G., Garnotel E., Djibo S., Caugant D.A. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005, 43(October (10)):5129-5135.
5. Coulson G.B., von Gottberg A., du Plessis M., Smith A.M., de Gouveia L., Klugman K.P. Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis 2007, 13(February (2)):273-281.
6. von Gottberg A., du Plessis M., Cohen C., Prentice E., Schrag S., de Gouveia L., et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46(February (3)):377-386.
7. Campbell J.D., Edelman R., King J.C., Papa T., Ryall R., Rennels M.B. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002, 186(December (12)):1848-1851.
8. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel M.J., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159(October (10)):907-913.
9. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(August (8346)):355-357.
10. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(August (3)):379-389.
11. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28(February (9)):2122-2129.
12. Huebner R.E., Klugman K.P., Matai U., Eggers R., Hussey G. Laboratory surveillance for Haemophilus influenzae type B meningococcal, and pneumococcal disease. Haemophilus Surveillance Working Group. S Afr Med J 1999, 89(September (9)):924-925.
13. Statistics South Africa P0302-Midyear Population Estimates 2005, Available at: http://www.statssa.gov.za/p. Accessed 28 July 2010.
14. Whitney A.M., Coulson G.B., von Gottberg A., Block C., Keller N., Mayer L.W., et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol 2009, 47(September (9)):2787-2793.
15. Sacchi C.T., Lemos A.P., Brandt M.E., Whitney A.M., Melles C.E., Solari C.A., et al. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 1998, 5(November (6)):845-855.
16. Thompson E.A., Feavers I.M., Maiden M.C. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149(July (Pt. 7)):1849-1858.
17. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998, 95(March (6)):3140-3145.
18. Beernink P.T., Caugant D.A., Welsch J.A., Koeberling O., Granoff D.M. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009, 199(May (9)):1360-1368.
19. Russell J.E., Urwin R., Gray S.J., Fox A.J., Feavers I.M., Maiden M.C. Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology 2008, 154(April (Pt. 4)):1170-1177.
20. Vicente D., Esnal O., Michaus L., Lopez de Goicoechea M.J., Cisterna R., Perez-Trallero E. Prevalence of genosubtypes (PorA types) of serogroup B invasive meningococcus in the north of Spain from 2000 to 2003. J Med Microbiol 2005, 54(April (Pt. 4)):381-384.
21. Baethgen L.F., Weidlich L., Moraes C., Klein C., Nunes L.S., Cafrune P.I., et al. Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing. Trop Med Int Health 2008, 13(January (1)):31-40.
22. Pace D., Cuschieri P., Galea D.A., Attard-Montalto S. Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines. Vaccine 2008, 26(November (47)):5952-5956.
23. Sorhouet P.C., Regueira M., Mollerach M. PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 2008, 57(March (Pt. 3)):338-342.
24. Sacchi C.T., Lemos A.P., Popovic T., De Morais J.C., Whitney A.M., Melles C.E., et al. Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997-1998: overview and implications for vaccine development. J Clin Microbiol 2001, 39(August (8)):2897-2903.
25. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(June (9580)):2196-2210.
26. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(December (2)):195-207.
27. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281(April (16)):1520-1527.
28. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(April (4)):2088-2100.
29. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362(April (16)):1511-1520.
30. Beernink P.T., Welsch J.A., Harrison L.H., Leipus A., Kaplan S.L., Granoff D.M. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007, 195(May (10)):1472-1479.
31. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(July):6086-6093.
32. Pillai S., Howell A., Alexander K., Bentley B.E., Jiang H.Q., Ambrose K., et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005, 23(March (17-18)):2206-2209.
33. Giuliani M.M., du-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103(July (29)):10834-10839.
34. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, (October).
35. Arora A. World vaccine congress. Expert Rev Vaccines 2009, 8(February (2)):135-138.
36. Richmond P., Marshall H., Sheldon E., Jiang Q., Anderson A., Jansen K., et al. Safety & immunogenecity of serogroup B (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. 17th International Pathogenic Neisseria Conference (IPNC) 2010.
37. Caugant D.A., Froholm L.O., Bovre K., Holten E., Frasch C.E., Mocca L.F., et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A 1986, 83(July (13)):4927-4931.
38. Cruz C., Pavez G., Aguilar E., Grawe L., Cam J., Mendez F., et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect 1990, 105(August (1)):119-126.
39. Grodet C., Dequin P.F., Watt S., Lanotte P., de Gialluly C., Taha M.K., et al. Outbreak in France of Neisseria meningitidis B:15:P1.12 belonging to sequence type 1403. Clin Microbiol Infect 2004, 10(September (9)):845-848.
40. Martin D.R., Walker S.J., Baker M.G., Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998, 177(February (2)):497-500.
41. Reeves M.W., Perkins B.A., Wenger J.D. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis 1995, 1(April (2)):53-54.
42. Rouaud P., Perrocheau A., Taha M.K., Sesboue C., Forgues A., du Chatelet I.P., et al. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveill 2006, 11(July (7)):178-181.
43. Sacchi C.T., Pessoa L.L., Ramos S.R., Milagres L.G., Camargo M.C., Hidalgo N.T., et al. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. J Clin Microbiol 1992, 30(July (7)):1734-1738.
44. Claus H., Elias J., Meinhardt C., Frosch M., Vogel U. Deletion of the meningococcal fetA gene used for antigen sequence typing of invasive and commensal isolates from Germany: frequencies and mechanisms. J Clin Microbiol 2007, 45(September (9)):2960-2964.
45. Marsh J.W., O'Leary M.M., Shutt K.A., Harrison L.H. Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates. J Clin Microbiol 2007, 45(April (4)):1333-1335.